Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ezetimibe add-on versus rosuvastatin dose doubling in primary hypercholesterolemia
2008-004953-14Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Oct 2008
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in hypercholesterolemia comparing Ezetimibe add-on to rosuvastatin with Rosuvastatin dose doubling (2 arms). Primary endpoint: Percent change from baseline in LDL-C. Started Oct 2008; status: completed.
02
Drugs
ezetimiberosuvastatin
03
Conditions
hypercholesterolemia
Beyond the preview
Go deeper on 2008-004953-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-004953-14.